FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973852893> ?p ?o ?g. }

• W1973852893 endingPage "491" @default.
• W1973852893 startingPage "487" @default.
• W1973852893 abstract "Few treatment options are available for cisplatin-refractory urothelial carcinoma. We evaluated the efficacy and safety of a new regimen composed of gemcitabine and ifosfamide as a second-line salvage chemotherapy for the disease. The gemcitabine and ifosfamide regimen consists of gemcitabine 800 mg/m2/day intravenously for 30 min on days 1, 8, and 15; ifosfamide 1500 mg/m2/day intravenously for 24 h on days 8–10; and mesna 800 mg intravenously bolus before ifosfamide and 1500 mg/m2/day intravenously for 24 h on days 8–11. Cycles are repeated every 28 days. Between 1998 and 2005, 23 patients (median age 66) unresponsive to cisplatin-based chemotherapy (n=10) or who had tumor progression within 6 months of a previous response to cisplatin-based therapy (n=13) were enrolled. The median interval between the two chemotherapy regimens was 1.8 months (range 0.9–5.6). In total, 82 treatment cycles (median 3, range 1–8) were given. The overall response rate was 22% (95% confidence interval 5–39) with one complete response and four partial responses. Twenty-one patients succumbed to the disease. The median progression-free survival and overall survival were 3.5 and 4.8 months, respectively. Grade 3 or 4 leukopenia and thrombocytopenia occurred in 10 and eight patients, respectively. One, two and two patients complicated with grade 3 vomiting, diarrhea and stomatitis were present, respectively. No grade 3 or 4 neurotoxicity or nephrotoxicity was seen in these patients. The gemcitabine and ifosfamide regimen has an acceptable toxicity profile, but shows insufficient clinical activity in patients with cisplatin-refractory urothelial carcinoma to warrant further testing." @default.
• W1973852893 created "2016-06-24" @default.
• W1973852893 creator A5010023514 @default.
• W1973852893 creator A5017953971 @default.
• W1973852893 creator A5030495726 @default.
• W1973852893 creator A5030951075 @default.
• W1973852893 creator A5071550613 @default.
• W1973852893 creator A5073467448 @default.
• W1973852893 creator A5081982339 @default.
• W1973852893 creator A5090591171 @default.
• W1973852893 date "2007-04-01" @default.
• W1973852893 modified "2023-10-16" @default.
• W1973852893 title "Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study" @default.
• W1973852893 cites W1500310443 @default.
• W1973852893 cites W1790466673 @default.
• W1973852893 cites W1827428051 @default.
• W1973852893 cites W1840050571 @default.
• W1973852893 cites W1858135205 @default.
• W1973852893 cites W1862964936 @default.
• W1973852893 cites W1953499160 @default.
• W1973852893 cites W1984429541 @default.
• W1973852893 cites W1998311214 @default.
• W1973852893 cites W2014960675 @default.
• W1973852893 cites W2036703045 @default.
• W1973852893 cites W2054341710 @default.
• W1973852893 cites W2064351590 @default.
• W1973852893 cites W2066984265 @default.
• W1973852893 cites W2076668534 @default.
• W1973852893 cites W2081911999 @default.
• W1973852893 cites W2084075250 @default.
• W1973852893 cites W2090906593 @default.
• W1973852893 cites W2103041841 @default.
• W1973852893 cites W2114859751 @default.
• W1973852893 cites W2133330931 @default.
• W1973852893 cites W2136968982 @default.
• W1973852893 cites W2151747207 @default.
• W1973852893 cites W2167805334 @default.
• W1973852893 cites W2268861790 @default.
• W1973852893 cites W2591247906 @default.
• W1973852893 cites W4246715702 @default.
• W1973852893 doi "https://doi.org/10.1097/cad.0b013e3280126603" @default.
• W1973852893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17351402" @default.
• W1973852893 hasPublicationYear "2007" @default.
• W1973852893 type Work @default.
• W1973852893 sameAs 1973852893 @default.
• W1973852893 citedByCount "38" @default.
• W1973852893 countsByYear W19738528932012 @default.
• W1973852893 countsByYear W19738528932013 @default.
• W1973852893 countsByYear W19738528932014 @default.
• W1973852893 countsByYear W19738528932015 @default.
• W1973852893 countsByYear W19738528932016 @default.
• W1973852893 countsByYear W19738528932017 @default.
• W1973852893 countsByYear W19738528932018 @default.
• W1973852893 countsByYear W19738528932019 @default.
• W1973852893 countsByYear W19738528932020 @default.
• W1973852893 countsByYear W19738528932022 @default.
• W1973852893 crossrefType "journal-article" @default.
• W1973852893 hasAuthorship W1973852893A5010023514 @default.
• W1973852893 hasAuthorship W1973852893A5017953971 @default.
• W1973852893 hasAuthorship W1973852893A5030495726 @default.
• W1973852893 hasAuthorship W1973852893A5030951075 @default.
• W1973852893 hasAuthorship W1973852893A5071550613 @default.
• W1973852893 hasAuthorship W1973852893A5073467448 @default.
• W1973852893 hasAuthorship W1973852893A5081982339 @default.
• W1973852893 hasAuthorship W1973852893A5090591171 @default.
• W1973852893 hasConcept C126322002 @default.
• W1973852893 hasConcept C126894567 @default.
• W1973852893 hasConcept C141071460 @default.
• W1973852893 hasConcept C2776694085 @default.
• W1973852893 hasConcept C2777506904 @default.
• W1973852893 hasConcept C2778239845 @default.
• W1973852893 hasConcept C2780258809 @default.
• W1973852893 hasConcept C2780376820 @default.
• W1973852893 hasConcept C2781413609 @default.
• W1973852893 hasConcept C71924100 @default.
• W1973852893 hasConcept C90924648 @default.
• W1973852893 hasConceptScore W1973852893C126322002 @default.
• W1973852893 hasConceptScore W1973852893C126894567 @default.
• W1973852893 hasConceptScore W1973852893C141071460 @default.
• W1973852893 hasConceptScore W1973852893C2776694085 @default.
• W1973852893 hasConceptScore W1973852893C2777506904 @default.
• W1973852893 hasConceptScore W1973852893C2778239845 @default.
• W1973852893 hasConceptScore W1973852893C2780258809 @default.
• W1973852893 hasConceptScore W1973852893C2780376820 @default.
• W1973852893 hasConceptScore W1973852893C2781413609 @default.
• W1973852893 hasConceptScore W1973852893C71924100 @default.
• W1973852893 hasConceptScore W1973852893C90924648 @default.
• W1973852893 hasIssue "4" @default.
• W1973852893 hasLocation W19738528931 @default.
• W1973852893 hasLocation W19738528932 @default.
• W1973852893 hasOpenAccess W1973852893 @default.
• W1973852893 hasPrimaryLocation W19738528931 @default.
• W1973852893 hasRelatedWork W181853034 @default.
• W1973852893 hasRelatedWork W1991291760 @default.
• W1973852893 hasRelatedWork W2006022537 @default.
• W1973852893 hasRelatedWork W2030818757 @default.
• W1973852893 hasRelatedWork W2033332523 @default.
• W1973852893 hasRelatedWork W2043437720 @default.

• next